Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5338K Administered Orally in Healthy Adult Males
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2018
At a glance
- Drugs PXS-5338K (Primary)
- Indications Hepatic fibrosis; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Pulmonary fibrosis; Renal fibrosis
- Focus Adverse reactions
- Sponsors Pharmaxis
- 11 Oct 2018 Results of this trial for first Lysyl Oxidase Like 2 (LOXL2) inhibitor (PXS-5338K) presented in an Arix Bioscience media release.
- 24 Sep 2018 The actual date of last participant enrollment is 5/6/2018
- 24 Sep 2018 Status changed from recruiting to completed.